|
|
泽布替尼在弥漫大B细胞淋巴瘤临床治疗中的应用研究进展
|
Abstract:
弥漫大B细胞淋巴瘤(DLBCL)是一种最常见的淋巴增生性疾病，侵袭性强且较难诊断。利妥昔单抗、环磷酰胺、阿霉素、长春新碱和强的松联合用药(R-CHOP)化学治疗方案是当前DLBCL患者的一线标准治疗方案，但约30%的DLBCL患者采用R-CHOP方案治愈后会复发，预后极差。布鲁顿酪氨酸激酶(BTK)是B细胞受体信号级联中的关键酶，泽布替尼作为不可逆的小分子BTK抑制剂，参与B淋巴细胞的生长、增殖和存活过程，可有效抑制恶性B淋巴细胞的增殖和存活。本文就泽布替尼在DLBCL患者临床治疗中的应用研究进展作一综述。
Diffuse large B-cell lymphoma (DLBCL) is one of the most common lymphoproliferative diseases, which is aggressive and difficult to diagnose. Chemotherapy with rituximab, cyclophosphamide, doxorubicin, chondrine, and prednisone (R-CHOP) is the current first-line standard of treatment for DLBCL patients, but about 30% of DLBCL patients will relapse after being cured with R-CHOP, and the prognosis is very poor. Bruton tyrosine kinase (BTK) is a key enzyme in the B-cell receptor signaling cascade. Zbrutinib, as an irreversible small-molecule BTK inhibitor, participates in the growth, proliferation and survival of B-lymphocytes and can effectively inhibit the proliferation and survival of malignant B-lymphocytes. This article reviews the research progress of the application of zebutinib in the clinical treatment of DLBCL patients.
| [1] | Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., et al. (2016) The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood, 127, 2375-2390. https://doi.org/10.1182/blood-2016-01-643569 |
| [2] | Wang, L., Li, L. and Young, K.H. (2020) New Agents and Regimens for Diffuse Large B Cell Lymphoma. Journal of Hematology & Oncology, 13, Article No. 175. https://doi.org/10.1186/s13045-020-01011-z |
| [3] | Gisselbrecht, C., Glass, B., Mounier, N., Singh Gill, D., Linch, D.C., Trneny, M., et al. (2010) Salvage Regimens with Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. Journal of Clinical Oncology, 28, 4184-4190. https://doi.org/10.1200/jco.2010.28.1618 |
| [4] | Duarte, D.P., Lamontanara, A.J., La Sala, G., Jeong, S., Sohn, Y., Panjkovich, A., et al. (2020) BTK SH2-Kinase Interface Is Critical for Allosteric Kinase Activation and Its Targeting Inhibits B-Cell Neoplasms. Nature Communications, 11, Article No. 2319. https://doi.org/10.1038/s41467-020-16128-5 |
| [5] | Bartlett, N.L., Costello, B.A., LaPlant, B.R., Ansell, S.M., Kuruvilla, J.G., Reeder, C.B., et al. (2018) Single-Agent Ibrutinib in Relapsed or Refractory Follicular Lymphoma: A Phase 2 Consortium Trial. Blood, 131, 182-190. https://doi.org/10.1182/blood-2017-09-804641 |
| [6] | Fares, A., Carracedo Uribe, C., Martinez, D., Rehman, T., Silva Rondon, C. and Sandoval-Sus, J. (2024) Bruton’s Tyrosine Kinase Inhibitors: Recent Updates. International Journal of Molecular Sciences, 25, Article 2208. https://doi.org/10.3390/ijms25042208 |
| [7] | Ou, Y.C., Liu, L., Tariq, B., Wang, K., Jindal, A., Tang, Z., et al. (2021) Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients with B‐Cell Malignancies. Clinical and Translational Science, 14, 764-772. https://doi.org/10.1111/cts.12948 |
| [8] | 许彭鹏, 赵维莅. 中国临床肿瘤学会淋巴瘤诊疗指南解读之弥漫性大B细胞淋巴瘤的规范治疗[J]. 华西医学, 2019, 34(4): 351-354. |
| [9] | Grimm, K.E. and O’Malley, D.P. (2019) Aggressive B Cell Lymphomas in the 2017 Revised WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Annals of Diagnostic Pathology, 38, 6-10. https://doi.org/10.1016/j.anndiagpath.2018.09.014 |
| [10] | 佟丹江. 弥漫大B细胞淋巴瘤的流行病学分析[J]. 中国现代药物应用, 2016, 10(8): 46-47. |
| [11] | Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., et al. (2000) Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling. Nature, 403, 503-511. https://doi.org/10.1038/35000501 |
| [12] | Morin, R.D., Mendez-Lago, M., Mungall, A.J., Goya, R., Mungall, K.L., Corbett, R.D., et al. (2011) Frequent Mutation of Histone-Modifying Genes in Non-Hodgkin Lymphoma. Nature, 476, 298-303. https://doi.org/10.1038/nature10351 |
| [13] | Morin, R.D., Mungall, K., Pleasance, E., Mungall, A.J., Goya, R., Huff, R.D., et al. (2013) Mutational and Structural Analysis of Diffuse Large B-Cell Lymphoma Using Whole-Genome Sequencing. Blood, 122, 1256-1265. https://doi.org/10.1182/blood-2013-02-483727 |
| [14] | Chaganti, S., Illidge, T., Barrington, S., Mckay, P., Linton, K., Cwynarski, K., et al. (2016) Guidelines for the Management of Diffuse Large B‐Cell Lymphoma. British Journal of Haematology, 174, 43-56. https://doi.org/10.1111/bjh.14136 |
| [15] | International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A Predictive Model for Aggressive Non-Hodgkin’s Lymphoma. New England Journal of Medicine, 329, 987-994. https://doi.org/10.1056/NEJM199309303291402 |
| [16] | Hitz, F., Connors, J.M., Gascoyne, R.D., Hoskins, P., Moccia, A., Savage, K.J., et al. (2015) Outcome of Patients with Primary Refractory Diffuse Large B Cell Lymphoma after R-CHOP Treatment. Annals of Hematology, 94, 1839-1843. https://doi.org/10.1007/s00277-015-2467-z |
| [17] | Gisselbrecht, C., Schmitz, N., Mounier, N., Singh Gill, D., Linch, D.C., Trneny, M., et al. (2012) Rituximab Maintenance Therapy after Autologous Stem-Cell Transplantation in Patients with Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. Journal of Clinical Oncology, 30, 4462-4469. https://doi.org/10.1200/jco.2012.41.9416 |
| [18] | Salles, G., Duell, J., González Barca, E., Tournilhac, O., Jurczak, W., Liberati, A.M., et al. (2020) Tafasitamab plus Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-MIND): A Multicentre, Prospective, Single-Arm, Phase 2 Study. The Lancet Oncology, 21, 978-988. https://doi.org/10.1016/s1470-2045(20)30225-4 |
| [19] | Sehn, L.H., Herrera, A.F., Flowers, C.R., Kamdar, M.K., McMillan, A., Hertzberg, M., et al. (2020) Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 38, 155-165. https://doi.org/10.1200/jco.19.00172 |
| [20] | Lin, J.K., Muffly, L.S., Spinner, M.A., Barnes, J.I., Owens, D.K. and Goldhaber-Fiebert, J.D. (2019) Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. Journal of Clinical Oncology, 37, 2105-2119. https://doi.org/10.1200/jco.18.02079 |
| [21] | van Dongen, J.M., Persoon, S., Jongeneel, G., Bosmans, J.E., Kersten, M.J., Brug, J., et al. (2019) Long-Term Effectiveness and Cost-Effectiveness of an 18-Week Supervised Exercise Program in Patients Treated with Autologous Stem Cell Transplantation: Results from the EXIST Study. Journal of Cancer Survivorship, 13, 558-569. https://doi.org/10.1007/s11764-019-00775-9 |
| [22] | Lu, T., Zhang, J., Xu-Monette, Z.Y. and Young, K.H. (2023) The Progress of Novel Strategies on Immune-Based Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Experimental Hematology & Oncology, 12. https://doi.org/10.1186/s40164-023-00432-z |
| [23] | Dienstmann, R., Bra？a, I., Rodon, J. and Tabernero, J. (2011) Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer Drugs. The Oncologist, 16, 1729-1740. https://doi.org/10.1634/theoncologist.2011-0163 |
| [24] | De Palma, M. and Hanahan, D. (2012) The Biology of Personalized Cancer Medicine: Facing Individual Complexities Underlying Hallmark Capabilities. Molecular Oncology, 6, 111-127. https://doi.org/10.1016/j.molonc.2012.01.011 |
| [25] | 贺诗雨, 黄琳. 新型口服布鲁顿酪氨酸激酶抑制剂——泽布替尼[J]. 临床药物治疗杂志, 2021, 19(8): 56-61. |
| [26] | Tam, C.S., Trotman, J., Opat, S., Burger, J.A., Cull, G., Gottlieb, D., et al. (2019) Phase 1 Study of the Selective BTK Inhibitor Zanubrutinib in B-Cell Malignancies and Safety and Efficacy Evaluation in CLL. Blood, 134, 851-859. https://doi.org/10.1182/blood.2019001160 |
| [27] | Das, M. (2019) Zanubrutinib in B-Cell Malignancies. The Lancet Oncology, 20, e470. https://doi.org/10.1016/s1470-2045(19)30523-6 |
| [28] | Coutre, S.E., Byrd, J.C., Hillmen, P., Barrientos, J.C., Barr, P.M., Devereux, S., et al. (2019) Long-Term Safety of Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia in 3 Pivotal Studies. Blood Advances, 3, 1799-1807. https://doi.org/10.1182/bloodadvances.2018028761 |
| [29] | Seiler, T. and Dreyling, M. (2017) Bruton’s Tyrosine Kinase Inhibitors in B-Cell Lymphoma: Current Experience and Future Perspectives. Expert Opinion on Investigational Drugs, 26, 909-915. https://doi.org/10.1080/13543784.2017.1349097 |
| [30] | Wilson, W.H., Young, R.M., Schmitz, R., et al. (2015) Targeting B Cell Receptor Signaling with Ibrutinib in Diffuse Large B Cell Lymphoma. Nature Medicine, 21, 922-926. |
| [31] | Hillmen, P., Brown, J.R., Eichhorst, B.F., Lamanna, N., O’Brien, S.M., Qiu, L., et al. (2020) ALPINE: Zanubrutinib versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Future Oncology, 16, 517-523. https://doi.org/10.2217/fon-2019-0844 |
| [32] | Yang, H., Xiang, B., Song, Y., Zhang, H., Zhao, W., Zou, D., et al. (2022) Zanubrutinib Monotherapy for Relapsed or Refractory Non-Germinal Center Diffuse Large B-Cell Lymphoma. Blood Advances, 6, 1629-1636. https://doi.org/10.1182/bloodadvances.2020003698 |
| [33] | 周佩瑶, 赵红玉, 杨文采, 李燕, 李大启. ZR2方案治疗老年难治性弥漫大B细胞淋巴瘤疗效观察[J]. 临床血液学杂志, 2022, 35(7): 495-499. |
| [34] | 石磊, 王亚丽, 孙恺, 等. 复发/难治DLBCL患者继发CNS侵犯的临床特征及泽布替尼联合化疗方案的疗效[J]. 山东医药, 2022, 62(19): 28-32. |
| [35] | Zhu, W., Tao, S., Miao, W., Liu, H. and Yuan, X. (2022) Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma after Failure to CD19-Targeted CAR-T Therapy. Frontiers in Immunology, 13, Article 894787. https://doi.org/10.3389/fimmu.2022.894787 |
| [36] | 杨婕, 魏婷, 许艳丽, 玉斌, 杨荧, 李庆山. 两种新型的BTK和HDAC抑制剂在弥漫性大B细胞淋巴瘤细胞中的协同抗肿瘤作用[J]. 中国病理生理杂志, 2023, 39(10): 1814-1822. |
